---
layout: post
title: 2010 New Drug Approvals - Pt. XVIII - Tesamorelin (Egrifta)
date: '2010-11-22T16:52:00.015Z'
author: Patricia
tags:
- Peptide Drugs
- 2010 New Drugs
modified_time: '2010-12-24T10:18:48.837Z'
thumbnail: http://2.bp.blogspot.com/_SlPG9DIz_AA/TPKFhCeP50I/AAAAAAAAA7s/Va8LUgdY-Z0/s72-c/20101117113618951.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-1005942751646225000
blogger_orig_url: http://chembl.blogspot.com/2010/11/2010-new-drug-approvals-pt-xviii.html
---

<div class="separator" style="clear: both; text-align: center;"><a href="http://2.bp.blogspot.com/_SlPG9DIz_AA/TPKFhCeP50I/AAAAAAAAA7s/Va8LUgdY-Z0/s1600/20101117113618951.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="229" src="http://2.bp.blogspot.com/_SlPG9DIz_AA/TPKFhCeP50I/AAAAAAAAA7s/Va8LUgdY-Z0/s320/20101117113618951.jpg" width="320" /></a></div><div style="text-align: center;"><br />
</div><div class="separator" style="clear: both; text-align: center;"><a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,0,0,1,0,1,0,0" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5506360071710601538" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,0,0,1,0,1,0,0" style="cursor: pointer; display: block; height: 47px; margin: 0px auto 10px; text-align: center; width: 400px;" /></a></div><div style="text-align: center;">ATC code (partial): H01AC<br />
<br />
</div>Also this month, on November 10th, FDA has approved Tesamorelin under the trade name Egrifta. Tesamorelin (research code:TH-9507) is an analog of the human <a href="http://en.wikipedia.org/wiki/Growth_hormone-releasing_factor">growth hormone-releasing factor (GRF)</a>&nbsp;(UniProt:<a href="http://www.uniprot.org/uniprot/P01286">P01286</a>, synonym:Somatoliberin, synonym:GRF, synonym:GHRH) indicated for the reduction of excess abdominal fat in <a href="http://en.wikipedia.org/wiki/HIV">HIV</a>-infected patients with <a href="http://en.wikipedia.org/wiki/Lipodystrophy">lipodystrophy</a>. Lipodystrophy is a condition in which excess fat develops in atypical areas of the body,  most notably around the liver, stomach, and other abdominal organs. This condition is observed as a side effect with many antiretroviral drugs used to treat HIV. Tesamorelin is the first-FDA approved treatment specifically approved for lipodystropy.<br />
<br />
The <i>-relin</i> INN stem covers prehormones or hormone releasing peptides, a very broad range of targets and pharmacology. The -morelin stem sub-group covers growth hormone-release stimulating peptides including capromorelin, dumorelin, examorelin, ipamorelin, pralmorelin, rismorelin, sermorelin, somatorelin, and tabimorelin.<br />
<br />
<br />
Tesamorelin is an N-terminally modified variant of the natural 44 residue long peptide, Somatoliberin, which is a hypothalamic peptide, acting on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous <a href="http://en.wikipedia.org/wiki/Growth_hormone">growth hormone (GH)</a>, which is both anabolic and lipolytic. Somatoliberin is a member of the glucagon family (Pfam:<a href="http://pfam.sanger.ac.uk/family/PF00123">PF00123</a>) of endogenous peptide ligands. Tesamorelin&nbsp;exerts its therapeutic effects by binding to, and being an agonist of GHRHr - <a href="http://en.wikipedia.org/wiki/Secretin_receptor_family">a type-2 (or class B, or secretin-like) GPCR</a> (Uniprot: <a href="http://www.uniprot.org/uniprot/Q02643">Q02643</a>, ChEMBL:<a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/158">CHEMBL158</a>, Pfam:<a href="http://pfam.sanger.ac.uk/family/PF00002">PF00002</a>), on pituitary somatotrophs; the triggered release growth hormone (GH) in turn acts on a variety of target cells, including <a href="http://en.wikipedia.org/wiki/Chondrocytes">chondrocytes</a>, <a href="http://en.wikipedia.org/wiki/Osteoblasts">osteoblasts</a>, <a href="http://en.wikipedia.org/wiki/Myocytes">myocytes</a>, <a href="http://en.wikipedia.org/wiki/Hepatocytes">hepatocytes</a> and <a href="http://en.wikipedia.org/wiki/Adipocytes">adipocytes</a>, resulting in a host of pharmacodynamic effects, which are primarily mediated by <a href="http://en.wikipedia.org/wiki/IGF-1">insulin-like growth factor 1 (IGF-1)</a> produced in the liver and in peripheral tissues.<br />
<br />
Tesamorelin has Molecular Weight of 5135.9 Da, absolute bioavailability, following <i>s.c.</i> dosing is less than 4%, with a volume of distribution of 10.5 L/kg (in HIV-infected patients) and an elimination half-life (t1/2) of 38 minutes (again in HIV-infected patients). The recommended dosage is 2 mg injected subcutaneously daily (typically in the abdomen) - a typical daily dose is therefore 0.39 umol).<br />
<br />
<a href="http://3.bp.blogspot.com/_GrFxGiayAGE/TOa2zrvssXI/AAAAAAAAAgA/W2eFQz59CbU/s1600/Tesamorelin.png" onblur="try {parent.deselectBloggerImageGracefully();} catch(e) {}"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5541317390558343538" src="http://3.bp.blogspot.com/_GrFxGiayAGE/TOa2zrvssXI/AAAAAAAAAgA/W2eFQz59CbU/s400/Tesamorelin.png" style="display: block; height: 125px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 0px; text-align: center; width: 400px;" /></a><br />
<div style="text-align: center;"><div style="text-align: auto;"><span class="Apple-style-span" style="color: #0000ee;"><u><span class="Apple-style-span" style="color: black;"><br />
</span></u></span></div></div><pre><i>trans</i>-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2</pre><pre></pre><pre></pre><br />
Tesamorelin is  produced synthetically and is otherwise identical in amino acid sequence to that of human Somatoliberin/GRF. Tesamorelin is then modified by attachment a 3-hexenoyl moiety <i>via</i> an amide linkage to the N-terminal tyrosine residue. This chemical modification blocks proteolytic degradation by endogenous proteins such as DPP-IV, thus prolonging the half-life of the peptide (the inhibition of DPP-IV is itself the basis of a number of therapies for the treatment of type-II diabetes - the gliptins). A further chemical modification is the C-terminal amidation - this <a href="http://en.wikipedia.org/wiki/Post_translational_modification">p.t.m.</a> is found in the naturally produced peptide. Tesamorelin is closely chemically related to a number of other clinical agents, such as Sermorelin (which is a shorter, but still active version of Somatoliberin/GRF)<br />
<br />
The full prescribing information can be found&nbsp;<a href="http://www.egrifta.com/Pdfs/EGRIFTA_PrescribingInformation_111110.pdf">here</a>.<br />
<br />
The license holder is <a href="http://www.emdserono.com/">EMD Serono, Inc.</a> and the product website is <a href="http://www.egrifta.com/">www.egrifta.com</a>.